Drug Profile
OR S1
Alternative Names: OR-S1Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; National Cancer Center (Tokyo)
- Class Antineoplastics
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in Japan (PO)
- 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)